RxDoctor Payments Data

Jennifer Liebenthal, MD

Neurology · Fairway, KSNPI 1205066446

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,116 of the $11,686 with a category attached, or 60.9%. Jazz Pharmaceuticals Inc. accounts for 74.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $8,830 and has fallen 78.1% since, to $1,930 in 2025.

$11,686in general payments, 2019–2025

Across 64 payments — averaging $182.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$9K
  • Inspire Medical Systems, Inc.$2K
  • Harmony Biosciences LLC$235
  • UCB, Inc.$205
  • Axsome Therapeutics, Inc.$146
  • Neurelis, Inc.$51
  • plus $70 from 3 others

What the payments were for

  • Speaking & faculty fees$7,11661%
  • Travel & lodging$1,74815%
  • Food & beverage$2,72723%
  • Education$951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,686 in reported general payments places this provider in the 85th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$150,425
Medicare patients
393
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SunosiSolriamfetol Hcl18$20,230
BelbucaBuprenorphine Hcl47$14,805
HorizantGabapentin Enacarbil20$13,738
BelsomraSuvorexant15$6,448
Jornay PmMethylphenidate Hcl11$4,909
Ramelteon27$3,105
Armodafinil33$2,574
Modafinil68$2,346
Eszopiclone33$740
Gabapentin80$738
Methylphenidate Hcl24$711
Pramipexole DihydrochloridePramipexole Di-Hcl18$471
Temazepam40$283
Clonazepam57$241
Trazodone Hcl40$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$146$20,23018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 131 neurology providers in Kansas.

Other neurology in Fairway

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →